Alp, EsmaCirak, TamerDemirbilek, MuratTurk, MustafaGuven, Eylem2020-06-252020-06-252017Alp E., Çırak T., Demirbilek M., Türk M., Güven E. (2017). Targeted delivery of etoposide to osteosarcoma cells using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles. Turkish Journal of Biology, 41(5), 719 - 733.1300-01521303-6092https://doi.org/10.3906/biy-1612-17https://hdl.handle.net/20.500.12587/7107CIRAK, Tamer/0000-0003-0431-9919; Alp, Esma/0000-0002-6650-0759; GUVEN, EYLEM/0000-0001-9039-1698Folic acid (FA)-functionalized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles were prepared to enhance the delivery efficiency of the anticancer drug etoposide for the clinical treatment of osteosarcoma. PHBV nanoparticles were synthesized by emulsification/solvent evaporation technique and obtained in the size range of 200-250 nm and zeta potential range of -21 and -27 mV. Encapsulation efficiency and in vitro drug release were studied. The cytotoxic, apoptotic, and necrotic effects of PHBV nanoparticles were also investigated using Saos-2 osteosarcoma cells. The results obtained in this study demonstrate that etoposide-loaded and FA-functionalized PHBV nanoparticles can be successfully used for targeted treatment of osteosarcoma.eninfo:eu-repo/semantics/openAccessPHBV nanoparticlefolate targetingetoposidetargeted drug deliveryosteosarcomaArticle41571973310.3906/biy-1612-172-s2.0-85034431227Q1244228WOS:000414903800004Q4